MERCK KGAA Your Contact
Bettina Frank
Phone +49 6151 72-4660
- Grants awarded to coincide with the 54th European Society for Paediatric Endocrinology (ESPE) Meeting
- Investment supports innovative projects for the advancement of science and medical research in the field of growth
Darmstadt, Germany, October 3, 2015 - Merck Serono, the biopharmaceutical business of Merck, today announced the recipients of the Grant for Growth Innovation (GGI) for 2015. The awards were handed over during the official award ceremony yesterday evening organized by Merck Serono in the light of the 54th European Society for Paediatric Endocrinology (ESPE) Meeting currently taking place in Barcelona, Spain.
Seventy applications were received from 21 countries, an increase of more than fifteen percent compared to the number of entries last year. The applications were reviewed by an independent Scientific Steering Committee composed of internationally renowned endocrinologists and chaired by Professor Christian Strasburger, Head of Clinical Endocrinology at the Charité Universitätsmedizin Berlin. Following a rigorous selection process two awards have been made to innovative projects which seek to advance understanding in the field of growth. The winning projects are based in the United Kingdom and the United States, and are as follows:
Page 1 of 3
Merck KGaAwww.merckserono.com Merck Serono is a business of Merck. Frankfurter Strasse 250
64293 Darmstadt
Germany
Hotline +49 (0) 6151 72-5000
www.merckgroup.com
Tel. +49 (0) 6151 72-4660
Bettina.Frank@merckgroup.com
University of Cambridge, Cambridge, UK
'Effects of insulin sensitisation on Insulin-Like Growth Factor-I levels in response to Growth Hormone treatment in children born small for gestational age.'
Edison Biotechnology Institute, Ohio University, Athens, OH, USA 'Experimental use of an alternative form of growth hormone.'
'Merck Serono is committed to supporting the advancement of science and medical research in the field of growth to deliver better outcomes for those living with growth hormone disorders. Following a successful debut last year, we are delighted that we had more entries from more countries for this year's Grant for Growth Innovation awards.' said Professor Steven Hildemann, Global Chief Medical Officer and Head of Global Medical Affairs and Safety at Merck Serono. Supporting those who are pioneering new research in growth disorders through the Grant for Growth Innovation reflects Merck Serono's belief that innovation is the cornerstone in releasing potential in the treatment of these diseases.
Notes to editors
Photos of the awards ceremony are available under www.grantforgrowthinnovation.org.
Merck Serono initiated the GGI program to support the advancement of understanding of the field of growth. A total grant of up to €400,000 per year divided between up to three research proposals will be awarded to one or more selected projects. Each application was blinded and evaluated by an independent Scientific Steering Committee composed of internationally renowned endocrinologists, according to five criteria: innovation; scientific rationale; clarity; feasibility; and impact of research.
For further information about the GGI and how to apply for next year's grants, please visit www.grantforgrowthinnovation.org
Merck Serono is the biopharmaceutical business of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.
Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.
For more information, please visit www.merckserono.com.
All Merck news releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe, to register online, change your selection or discontinue this service.
Merck is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses - Merck Serono, Consumer Health, Allergopharma, Biosimilars, Merck Millipore and Performance Materials - and generated sales of € 11.3 billion in 2014. Around 39,000 employees work for Merck in 66 countries to improve the quality of life for patients, to foster the success of customers, and to help meet global challenges. Merck is the world's oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.
|
distributed by
|
